5 Most Undervalued Pharma Stocks to Invest In

3. Novo Nordisk A/S (NYSE:NVO)

PE Ratio: 10.66

Novo Nordisk A/S (NYSE:NVO) is one of the most undervalued stocks to invest in.

TheFly reported on May 27 that NVO announced that it will present new clinical findings from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, scheduled for June 5–8, 2026. The company plans to showcase results from its Phase 3 REIMAGINE program evaluating investigational CagriSema on blood sugar control and weight reduction across multiple type 2 diabetes treatment backgrounds. In total, 40 scientific abstracts will be presented at the meeting. This includes Phase 2 data on the safety and efficacy of once-weekly injectable zenagamtide, along with updated clinical evidence for Ozempic and Wegovy, further expanding research on semaglutide across several cardiometabolic indications.

Separately, earlier on May 12, Novo Nordisk A/S (NYSE:NVO) presented new clinical and real-world evidence for Wegovy (semaglutide 2.4 mg and 7.2 mg) at the European Congress on Obesity 2026 in Istanbul. The data showed consistent and significant weight reduction in women with obesity across different stages of reproductive life, including premenopause, perimenopause, menopause, and postmenopause. Findings were drawn from the STEP UP trial, the SELECT cardiovascular outcomes study, and a large real-world analysis. Results also indicated improvements in waist circumference, body composition, cardiovascular risk reduction, and quality of life measures such as migraine, depression, and menopause-related symptoms, reinforcing semaglutide’s broader cardiometabolic benefits.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company focused on diabetes, obesity, and rare bleeding disorders. Headquartered in Denmark, it is one of the world’s largest insulin producers.